Pharmaceuticals & Biopharmaceuticals

Conshohocken, Pa. – – September 30, 2026 -- Suvoda has released a unified clinical trial technology platform that merges its RTSM systems with Greenphire's financial management tools, cutting kickoff-to-UAT timelines by up to 80% through new agentic AI capabilities.

Agentic AI Slashes Setup Times Across RTSM and eCOA

Suvoda's new AI layer, starting with randomization and trial supply management (RTSM) and electronic clinical outcome assessment (eCOA), is delivering the 80% reduction in kickoff-to-UAT timelines. A conversational assistant called Sofia allows sponsors and sites to query data and execute permissioned actions across multiple languages, with every action logged for audit purposes while humans retain final sign-off authority.

Secaucus, N.J. – September 30, 2026 -- Pierre Fabre Pharmaceuticals Inc. (PFP) has resubmitted a Biologics License Application to the U.S. Food and Drug Administration for tabelecleucel, seeking approval as a monotherapy for adult and pediatric patients aged 2 and older with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed at least one prior therapy.

Resubmission follows April 2026 FDA alignment meeting

PFP filed the updated application after reaching agreement with the FDA during an April 2026 Type A meeting. The package includes an expanded dataset with additional patients and longer follow-up from the pivotal Phase 3 ALLELE study, which evaluates tabelecleucel in patients with EBV+ PTLD following hematopoietic cell transplant (HCT) or solid organ transplant (SOT).

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

Trial enrolled 221 patients with moderate-to-severe hand and foot atopic dermatitis

The randomized, double-blind, placebo-controlled ADtouch trial (NCT06921759) assigned 221 adults and adolescents 1:1 to EBGLYSS 250 mg or placebo every two weeks over 16 weeks, following an initial loading dose. Participants had an inadequate response to topical therapies and applied moisturizer throughout the study.

Barcelona – September 30, 2026 -- Servier is standardizing customer reference data across more than 80 countries using Veeva OpenData, part of a global push to build an AI-ready data foundation for its commercial and medical teams.

Servier scales AI infrastructure after prior success with Veeva Link Key People

The French pharmaceutical company, governed by a Foundation, is harmonizing customer reference data globally to create a unified semantic layer that connects with Veeva Link. Liam Hanrahan, director of world operations excellence at Servier, said the move goes beyond process improvement, calling it the construction of a global data foundation designed to redefine how the company operates and scale AI across its affiliates.

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

Patients switching to the oral formulation saw rapid weight-loss gains after three months

The retrospective analysis of 194 patients on the Ro telehealth platform found that 40.7% achieved weight loss of 5% or more within three months of switching from injectable semaglutide or tirzepatide to once-daily oral semaglutide (p0.001). The proportion of participants classified with a BMI of 30 kg/m2 or higher fell by 21.6 percentage points, dropping from 87.1% at baseline to 65.5% at the three-month mark.

Groton, Conn. – September 30, 2026 -- Astrocyte Pharmaceuticals Inc. has closed a $9.5 million Series B financing round to advance Phase 2 development of AST-004, its cerebroprotective therapy for concussion, traumatic brain injury (TBI) and stroke. The round brings total capital raised by the clinical-stage biotech, including grants, to $40 million.

DeepWork Capital leads financing with four new investors joining the round

The Series B was led by DeepWork Capital, with continued backing from existing investors and new participation from MintPharma Capital, Waterstar Capital, Dynagrow Capital and Angel Star Ventures. Jackson Streeter, M.D., Venture Partner at DeepWork Capital, said the firm has been impressed by the consistency of Astrocyte's science and the progress of its clinical programs.

Stockholm – – September 30, 2026 -- EQT Foundation has committed more than EUR 1 million to 11 research projects across 10 institutions aimed at solving one of neuroscience's most persistent commercial barriers: getting therapeutics past the blood-brain barrier and into the central nervous system.

Eleven projects target the blood-brain barrier from different scientific angles

The funded research spans engineered biological carriers, molecular shuttles, gene therapy vectors, nanoparticles and AI-designed delivery technologies. Institutions involved are located in the Netherlands, Belgium, the United States and Canada, with initial disease applications including brain cancer, ALS and rare genetic disorders.

London – September 30, 2026 -- Clarenta Group has taken a majority stake in Leads To Development (L2D), a Paris-based preclinical and regulatory consultancy, expanding its reach into early-stage drug development ahead of first-in-human trials.

Clarenta adds non-clinical and manufacturing expertise to its clinical development platform

L2D specializes in defining development pathways, assessing preclinical evidence, troubleshooting manufacturing processes, and building regulatory strategies for biotech and pharmaceutical sponsors. The addition connects this early-stage scientific work directly to Clarenta's existing Early Phase Unit and clinical consulting capabilities.

Cambridge, Mass. – September 30, 2026 -- Insilico Medicine (HKEX: 3696) has nominated ISM1354, an AI-designed small molecule GIPR antagonist, as a preclinical candidate for obesity, type 2 diabetes and potential cardiovascular applications tied to obesity-associated heart failure.

ISM1354 improves on Insilico's earlier GIPR candidate ISM0676

Washington – September 30, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) reported positive topline results from a pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD), setting up a supplemental New Drug Application (sNDA) filing with the U.S. Food and Drug Administration (FDA).

Trial meets primary endpoint with statistically significant sleep-timing shift

The study, VP-VEC-162-3502 (NCT04652882), shifted sleep onset 42.5 minutes earlier in the HETLIOZ® arm (n=20) versus 5.4 minutes on placebo (n=20), a 37.1-minute difference (p=0.022). In an exploratory responder analysis, 60% of tasimelteon-treated participants (12/20) advanced sleep onset by at least 30 minutes, compared with 15% on placebo (3/20) (p=0.008).